Genomic landscape of cell-free DNA in patients with colorectal cancer

John H. Strickler¹, Jonathan M. Loree², Leanne G. Ahronian³, Aparna R. Parikh³, Donna Niedzwiecki¹, Allan Andresson Lima Pereira², Matthew Mckinney¹, W. Michael Korn⁴,⁵, Chloe E. Atreya⁴, Kimberly C. Banks⁶, Rebecca J. Nagy⁶, Funda Meric-Bernstam², Richard B. Lanman⁶, AmirAli Talasaz⁶, Igor F. Tsigelny⁷,⁸, Ryan B. Corcoran³ #, Scott Kopetz² #

¹Duke University Medical Center, Durham, NC, USA; ²University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA; ⁴Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; Caris Life Sciences, Phoenix, AZ, USA; ⁶Guardant Health, Inc., Redwood City, CA, USA; ⁷University of California San Diego, San Diego, CA, USA; ⁸CureMatch Inc., San Diego, CA, USA.

#To whom correspondence should be addressed:

Dr. Ryan B. Corcoran
Massachusetts General Hospital Cancer Center, 149 13th St., 7th floor
Boston, MA 02129
Phone: 617-726-8599
Fax: 617-724-9648
Email: rbcorcoran@partners.org

Dr. Scott Kopetz
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426
Houston, TX 77030
Phone: 713-792-2828
Fax: 713-563-2957
Email: skopetz@mdanderson.org
Running Title: Cell-free DNA sequencing in colorectal cancer

Key words: Cell-free DNA, circulating tumor DNA, colorectal cancer

Disclosure of potential conflicts of interest:
R.B.C. is a consultant/advisory board member for Amgen, Astex Pharmaceuticals, Avidity Biosciences, BMS, Genentech, Merrimack, N-of-one, Roche, Shire, and Taiho, and has received research funding from AstraZeneca and Sanofi.

J.H.S is a consultant/advisory board member for Amgen, Celgene, Genentech/Roche, Bayer, and Boehringer Ingelheim and has received research funding from Abbvie, Gilead Sciences, Roche/Genentech, Exelixis, Bayer, Cascadian Therapeutics, OncoMed, Sanofi, Regeneron, and MedImmune.

A.R.P was a former employee of Genentech/Roche.

W.M.K is an employee and shareholder of Caris Life Sciences and is a consultant/advisory board member for Lilly, Merck, and Guardant Health.

C.E.A is a consultant/advisory board member for Genentech/Roche and Kura Oncology. UCSF has received research funding from Bristol-Myers Squibb, Merck, Novartis, and Guardant Health.


S.K. is a consultant/advisory board member for Amgen, Bayer, EMD Serono, Genentech, MedImmune, Merrimack, Merck, Roche, Sanofi, Symphogen, Taiho. MD Anderson has received research funding from Guardant Health.
Grant Support:
The work is supported by NIH R01 CA184843 (to S.K.), by a CPRIT grant RP150535 (to F.M.B.), by an ASCO Young Investigator Award, Canadian Association of Medical Oncologists Research Fellowship, and Detweiler Fellowship (to J.M.L.), NIH/NCI K08CA175143 (to C.E.A), and by a Damon Runyon Clinical Investigator Award, NIH/NCI Gastrointestinal Cancer SPORE P50 CA127003, R01CA208437, K08CA166510, Research supported by a Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant (Grant Number: SU2C-AACR-DT22-17). Stand Up to Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C (to R.B.C).
Abstract
“Liquid biopsy” approaches analyzing cell-free DNA (cfDNA) from the blood of cancer patients are increasingly utilized in clinical practice. However, it is not yet known whether cfDNA sequencing from large cancer patient cohorts can detect genomic alterations at frequencies similar to those observed by direct tumor sequencing, and whether this approach can generate novel insights. Here, we report next-generation sequencing data from cfDNA of 1,397 colorectal cancer (CRC) patients. Overall, frequencies of genomic alterations detected in cfDNA were comparable to those observed in three independent tissue-based CRC sequencing compendia. Our analysis also identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding of anti-EGFR antibodies. Patients with EGFR ECD mutations displayed striking tumor heterogeneity, with 91% harboring multiple distinct resistance alterations (range 1-13, median 4). These results suggest that cfDNA profiling can effectively define the genomic landscape of cancer and yield important biologic insights.

Significance
This study provides one of the first examples of how large-scale genomic profiling of cfDNA from patients with colorectal cancer can detect genomic alterations at frequencies comparable to those observed by direct tumor sequencing. Sequencing of cfDNA also generated insights into tumor heterogeneity and therapeutic resistance, and identified novel EGFR ectodomain mutations.
Introduction

Next-generation sequencing (NGS) of tumor tissue specimens from large patient cohorts has led to major advances in elucidating the genomic landscape of cancer. Despite the many benefits and therapeutic insights offered by this approach, large-scale genomic profiling through tissue-based sequencing methods is not without limitations. Importantly, to be suitable for sequencing, tissue samples must be of adequate quantity and must possess a sufficient percentage of tumor cells amongst a background of normal cells and stroma. While many surgical resection specimens are of suitable quality, needle-based biopsy samples from metastatic lesions often yield insufficient tumor cells to produce robust sequencing data (1,2). As a result, many tumor tissue sequencing databases are derived from earlier stage, largely untreated cancers, as opposed to tumors from patients with metastatic disease, where small biopsies are typically performed (3,4). Thus, tissue-based sequencing compendia may not accurately represent the genomic landscape and biology of advanced cancers.

With the recent increase in clinical cell-free DNA (cfDNA) testing, large cfDNA-based sequencing databases could represent an attractive resource for genomic studies. However, it is not yet known if the genomic landscape defined by population-based cfDNA sequencing accurately reflects the genomic landscape of mutations identified in large tissue-based sequencing studies. CfDNA represents DNA present in the non-cellular portion of blood that originates from either normal tissue or tumor sources. The tumor-derived portion of cfDNA is termed circulating-tumor DNA (ctDNA) and represents DNA that is shed into the bloodstream by tumor cells throughout the body. CfDNA testing offers access to tumor DNA, regardless of whether a surgery or biopsy is clinically indicated, thus protecting patients with metastatic disease from potential complications of an invasive procedure. Furthermore, since cfDNA can be shed into the blood from multiple lesions in an individual patient, it can offer an anatomically unbiased
sampling of primary and metastatic tumor lesions, thereby generating insights into intra- and inter-tumoral heterogeneity (5-12). Therefore, understanding the key similarities and differences between cfDNA and tissue-based tumor databases would be informative in determining whether large-scale cfDNA profiling might represent an effective and efficient approach to define the mutational landscape of specific cancer types.

Here, we report results from clinical cfDNA testing of 1,397 de-identified individual patients with advanced colorectal cancer (CRC), and compare these results to three independent large-scale tissue-based sequencing databases. We find that cfDNA profiling detects genomic alterations at frequencies comparable to those previously reported by direct tumor sequencing. Our findings also reveal how analysis of large cfDNA sequencing databases can provide novel and clinically relevant insights into tumor heterogeneity and therapeutic resistance.

Results

Comparison of the mutational landscape of cfDNA and tumor tissue

To assess the potential utility of a large cfDNA sequencing database, we analyzed 1,772 consecutive blood specimens from patients with CRC who underwent testing with a targeted next-generation sequencing assay (Guardant360™, Guardant Health) between 6/1/2014 and 5/18/2016. There were three versions of the assay during the study time period, covering 54, 68, and 70 genes, respectively (Supplementary Table S1). In all, 1500 cases (85%) had at least one genomic alteration detectable in cfDNA. Of these, 103 samples represented serial assays from the same patient, leaving 1,397 unique patients with genomic data for analysis (Supplementary Figure S1).
The prevalence of non-synonymous single nucleotide variants (SNVs) detected in cfDNA was compared to those observed in three publicly available CRC tissue-based databases, including The Cancer Genome Atlas (TCGA) (n=228) (3), the Nurses Health Study/Health Professionals Follow-Up Study (NHS/HPFS) (n=619) (4), and the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) (n=1,149) (13). For consistency, the analysis of all cohorts was adjusted to include only those SNVs covered by the cfDNA assay. Mutational prevalence was largely consistent between the three tissue cohorts (Fig. 1A), though some small differences were observed, which may be due to expected statistical variability, or to differences in demographics between the three tissue cohorts. For example, the increased prevalence of BRAF mutations in the NHS/HPFS cohort is likely due to the increased representation of women in this cohort (BRAF mutations are more common in women than men with CRC) (Supplementary Table S2). Overall, there were striking similarities in mutational prevalence between cfDNA and the three tissue-based databases (Fig. 1A, Supplementary Table S3). The mutational prevalence of the twenty most commonly mutated genes in cfDNA was strongly associated with the mutational prevalence in tumor tissue (R^2 = 0.95; p<0.0001) (Fig. 1B). Still, there were some notable differences between cfDNA and tissue. For example, EGFR mutations were significantly more common in cfDNA (11.2%) than tissue (4.8% for TCGA [p<0.003], 4.4% for NHS/HPFS [p<0.0001], and 2.9% for GENIE [p<0.0001], by chi-squared test) (Fig. 1A). These differences may reflect real biological differences between the cfDNA and tissue-based cohorts, as patients who received cfDNA profiling were more likely to have metastatic disease and to have received prior therapies.

Additionally, JAK2 V617F mutations were detected in the cfDNA of 16 patients, but none of the 1,996 combined CRC specimens profiled from the tissue-based sequencing databases (Fig. 1C). The most likely explanation for this discrepancy is that JAK2 V617F mutations detected in cfDNA were not actually present in the patients’ tumors, but were present in a hematopoietic clone of
indeterminate clinical potential, which is observed in 0.2% of the general population (14). Indeed, JAK2 V617F mutations are one of the most common mutations observed in hematopoietic clones of indeterminate clinical potential, and these mutations increase in prevalence with age (15). Consistent with this hypothesis, the median age for patients with a JAK2 V617F mutation detected in cfDNA was 73 years, whereas the median age among patients without this mutation was 60 years (p=0.0006) (Fig. 1D). This example highlights an important limitation of blood-based genomic profiling, in that one cannot be certain that a mutation detected in cfDNA is actually derived from the patient’s tumor. Still, these data overall show a remarkably high similarity between cfDNA-based and tissue-based profiling, and as a whole support the potential utility and validity of large-scale cfDNA genomic profiling approaches.

Comparison of clonal and subclonal mutations

We then evaluated the clonal versus subclonal landscape of mutation variants detected in the CRC cfDNA cohort. A mutation was defined as “subclonal” if the mutant allele frequency (MAF) was less than 25% of the highest MAF in the sample, and was defined as “clonal” if it was above this threshold. At least one subclonal mutation was found in 51% of patients (range of 1 to 54 subclonal mutations). Among the twenty genes with the highest mutational prevalence in cfDNA, the six genes most likely to be clonal (in order of most to least clonal) include KRAS, FBXW7, APC, SMAD4, BRAF, and TP53 (Fig. 2A), all of which are known to play early and critical events in the oncogenesis of CRC. Furthermore, clonal SNVs were significantly more likely to represent mutations predicted to be activating or inactivating truncal driver mutations, while subclonal SNVs were more likely to be non-functioning “passenger” mutations or variants of unknown significance (OR 3.65, 95% CI 3.24-4.10, P<0.0001) (Fig. 2B).
We hypothesized that another class of subclonal mutations could represent non-truncal acquired resistance mutations emerging during prior therapy. Interestingly, EGFR was the gene with the highest percentage of subclonal mutations (Fig. 2A). When the MAFs of two predominantly clonal mutations—KRAS and APC—were compared in individual tumors, a linear relationship was observed (Fig. 2C), suggesting that these mutations often coexist as clonal events in CRC, although some subclonal KRAS and APC mutations were noted. However, when the MAFs of EGFR and APC SNVs were compared, a linear relationship was not observed, with most EGFR mutations occurring at subclonal frequencies (Fig. 2D). This suggests that the EGFR mutations detected in cfDNA are not likely to be founding clonal events in the development of these CRCs, but rather are likely to be mutations emerging in specific tumor subclones, either as part of the process of tumor progression or metastasis, or perhaps in response to the selective pressure of anti-cancer therapies.

Consistent with this latter hypothesis, many of the patients with subclonal EGFR mutations harbor specific mutations in the extracellular domain (ECD) of EGFR. EGFR ECD mutations have been implicated in driving clinical acquired resistance to anti-EGFR antibodies, such as cetuximab and panitumumab, which are approved for the treatment of KRAS and NRAS (RAS) wild type metastatic CRC (7,12,16-18). Similarly, many of the subclonal KRAS mutations observed also occurred in these same patients with EGFR ECD mutations (Fig. 2C, red labels). KRAS and NRAS (RAS) mutations are another common mechanism of acquired resistance that can emerge during therapy with anti-EGFR antibodies, and prior studies have shown that subclonal RAS and EGFR ECD mutations can emerge in the same patient during anti-EGFR therapy (9,19). The substantially higher mutation prevalence of EGFR mutations in cfDNA compared to tissue (Figs. 1A, B) may thus reflect the emergence of subclonal resistance mutations, particularly in the setting of acquired EGFR antibody resistance.
EGFR extracellular domain mutations in cfDNA of CRC patients

To evaluate the potential for large-scale cfDNA sequencing to provide clinically relevant insights into therapeutic resistance, we performed a focused analysis on patients with EGFR mutations. In total, 85 of 157 patients with EGFR mutations had mutations in the extracellular domain (amino acids 1 through 649) (Fig 3A). To identify mutations with the greatest likelihood of functional relevance, we focused on EGFR ECD mutations that were recurrent (observed in more than one patient) in this cohort. In total, 58 patients harbored a recurrent EGFR ECD mutation, and in 42 patients these EGFR ECD mutations occurred in domain III of EGFR (amino acids 334-504), which represents the binding epitope of both cetuximab and panitumumab (Fig. 3A). Of these 42 patients, all 24 (57%) patients with available treatment histories were confirmed to have received anti-EGFR antibody treatment prior to blood collection for cfDNA analysis, supporting a likely role for these mutations in driving therapeutic resistance. Treatment histories for the remaining 18 patients were not available.

Analysis of the EGFR ECD mutations from these 42 patients revealed 23 distinct mutations in 11 amino acids in domain III. Seven of these amino acids clustered into two regions—Cluster 2 (I462, S464, G465, K467) and Cluster 3 (K489, I491, S492)—previously reported to be associated with cetuximab and/or panitumumab resistance (Fig. 3A) (7,10,12,18). Mutations in two amino acids, F404 and T415, were noted in a small percentage of patients and have not been previously reported in anti-EGFR antibody resistance. However, mutations in two additional amino acids not previously implicated in anti-EGFR antibody resistance—V441 and S442—formed a prominent new cluster (Cluster 1) accounting for 25% of all EGFR ECD mutations. The majority of these novel but highly recurrent mutations affected V441, with V441D and V441G being the most common amino acid changes observed.
To explore the hypothesis that V441D and V441G represent novel mechanisms of acquired resistance to anti-EGFR antibodies, we performed molecular modeling to predict the effects of these mutations on cetuximab binding to EGFR. Compared to wild-type EGFR, the V441D mutation introduces a negatively charged residue that is predicted to decrease the interaction between cetuximab and EGFR (Fig. 3B). Similarly, the V441G mutation is predicted to destroy a critical hydrophobic node, decreasing the interaction between cetuximab and EGFR (Fig. 3C). Consistent with these models, both the V441D and V441G EGFR mutants showed significantly reduced binding of both cetuximab and panitumumab, relative to wild type EGFR (Fig. 3D), supporting their role as novel mechanisms of acquired resistance to anti-EGFR antibodies.

**Heterogeneity of anti-EGFR antibody resistance**

To further investigate the impact of tumor heterogeneity on therapeutic strategies to overcome anti-EGFR antibody resistance, we performed an in-depth analysis of the cfDNA profiles from the 42 patients with *EGFR* ECD mutations. In addition to *EGFR* ECD mutations, multiple mechanisms of acquired resistance to anti-EGFR antibodies that bypass the need for EGFR signaling have been previously identified, including alterations in *KRAS, NRAS, BRAF, MAP2K1, ERBB2, MET,* and *KIT* (5-7,10-12,16,18,20-25). We observed that in 91% of patients with *EGFR* ECD mutations in cfDNA, at least one additional co-occurring resistance alteration was also detected in cfDNA. On average, these patients harbored 5 distinct resistance alterations to anti-EGFR antibodies (median 4), with as many as 13 co-occurring resistance alterations being detected in a single patient, indicating a striking degree of heterogeneity (Fig. 4A). These co-occurring resistance alterations frequently involved multiple functionally distinct gene targets with 54 unique alterations noted affecting eight different genes. *KRAS* alterations (including mutations and amplifications) were the most common resistance alterations observed, present in 69% of patients. *KRAS* mutations
occurred in 62% of patients, with KRAS Q61H being the most common, observed in 52% of patients. MET amplification, NRAS mutations, and KRAS amplification were the next most common resistance alterations observed, present in 38%, 33%, and 24% of cases, respectively. BRAF and MAP2K1 mutations were each present in 9.5% of cases.

The presence of multiple resistance alterations in the cfDNA of an individual patient is thought to represent the existence of multiple resistant tumor subclones that have emerged during therapy, which perhaps reside in different metastases throughout the body. Consistent with this model, resistance mutations were significantly more likely to be subclonal in patients with multiple concurrent mechanisms of resistance compared to patients with only a single mechanism of resistance to anti-EGFR therapy (54.5% vs 10.0%, P<0.0001, OR 10.81, 95% CI 7.83-14.93) (Supplementary Figure S2). Indeed, we observed that patients with EGFR ECD mutations showed an enrichment of subclonal EGFR and KRAS mutations relative to the overall cohort (Figs 2C, D, red labels). Our analysis also revealed profound heterogeneity occurring in the context of acquired resistance. For example, one patient (Fig 4B, pt #1) harbored 13 distinct resistance alterations, including four EGFR ECD mutations, four KRAS mutations, KRAS amplification, two NRAS mutations, ERBB2 amplification, and a downstream mutation affecting MEK1 (encoded by MAP2K1). Another patient (Fig 4B, pt #8) harbored eight different resistance alterations, including two EGFR ECD mutations, as well as MET amplification, ERBB2 amplification, KIT amplification, KRAS Q61H, and BRAF V600E. A third patient (Fig 4B, pt #12) harbored seven different resistance alterations, including two EGFR ECD mutations, MET amplification, and KRAS, NRAS, BRAF, and MAP2K1 mutations. In another patient with serial cfDNA analyses and detailed treatment history, multiple resistance alterations were observed to emerge during anti-EGFR therapy (Supplementary Fig S3). This degree of heterogeneity and the co-occurrence of multiple distinct resistance alterations present a daunting
challenge for therapeutic strategies designed to overcome resistance to anti-EGFR antibodies.

In an effort to overcome acquired resistance, anti-EGFR antibody mixtures, such as Sym004 and MM-151, have been developed that are capable of binding multiple epitopes on EGFR and can thereby overcome the effects of individual EGFR ECD resistance mutations. However, these agents may not overcome non-ECD resistance alterations that bypass the requirement for EGFR signaling via activation at other points in the RAS-RAF-MEK-ERK pathway. Importantly, of the 42 patients harboring domain III EGFR ECD mutations identified in our analysis, 88% harbored at least one additional non-ECD resistance alteration detectable in cfDNA that would be predicted to drive resistance to an EGFR antibody mixture alone (Fig. 4C), with an average of 2.9 non-ECD resistance alterations per patient (range 1-9, median 3).

**Discussion**

With the growing utilization of clinical cfDNA testing, large cfDNA sequencing databases could represent a valuable resource for genomic discovery. Here, we present one of the first studies assessing whether large-scale genomic profiling of cfDNA can accurately reproduce the genomic landscape of driver mutations defined by direct tumor tissue sequencing studies. In our analysis of the cfDNA profiles of 1,397 patients with CRC, we find that the spectrum and frequency of genomic alterations identified in cfDNA demonstrate a striking similarity with results from three large CRC tumor tissue sequencing cohorts. These data provide a key proof-of-concept supporting the feasibility and validity of large-scale genomic analysis of cfDNA.

Genomic profiling from cfDNA offers potential advantages and limitations when compared to tumor tissue-based sequencing. One key limitation to tumor tissue sequencing is that up to 25% of patients with advanced cancer may have
insufficient quantity of tissue available for molecular analysis (2). In contrast, since peripheral blood can be collected efficiently and non-invasively, cfDNA testing can be performed on almost any patient, including those with tumor lesions that are difficult to biopsy. Furthermore, as tumor tissue sequencing often relies on archival tissue obtained prior to the development of metastatic disease, cfDNA profiling may more readily facilitate analysis of patients with metastatic disease, and may better capture the presence of tumor heterogeneity.

However, cfDNA profiling also has limitations. In this dataset, genomic alterations in cfDNA were not detected in 15% of cases. This result is similar to rates of cfDNA detection in other CRC series (5,19), and is comparable to the rate of tissue insufficiency in tissue-based NGS profiling (2). While it is possible that some patients did not have alterations in genes covered by the NGS assay, in most cases, lack of detection of genomic alterations in cfDNA was likely due to other factors, including low tumor burden, lack of cfDNA shedding by some tumors, and timing of blood collection (ctDNA is reduced after surgical resection and while on active treatment) (26). Optimizing the timing of cfDNA testing—for example, prior to initiation of therapy or at the time of disease progression—may be an important means of increasing the yield of cfDNA testing.

Another limitation of cfDNA profiling highlighted in our study, is that it is possible for both tumor-derived and non-tumor-derived genomic alterations to be detected in cfDNA, which has the potential to confound analyses (27). For example, in our study, JAK2 V617F mutations were detected in cfDNA from 1.1% of patients, but in none of the CRC cases from tissue-based cohorts (Fig. 1C). These JAK2 V617F mutations are most likely derived from a hematopoietic clone of indeterminate clinical potential, which is observed sub-clinically in the peripheral blood in a small percentage of the general population, but with increasing prevalence with age (14). Indeed, these mutations were found predominantly in older patients in our cohort (Fig. 1D). Similarly, a recent case report identified an IDH2 mutation in cfDNA from a patient with metastatic CRC that was not readily
detectable in a matched tumor biopsy. The same IDH2 mutation was identified in a bone marrow biopsy, supporting that the alteration originated from a hematopoietic clone (28). Going forward, methods such as parallel sequencing of mononuclear cells isolated from peripheral blood may help to delineate whether specific alterations detected in cfDNA are derived from clonal hematopoiesis or tumor (27).

In addition to illustrating the close relationship between the genomic landscape of cfDNA and tissue, our study also offers unique insights into therapeutic resistance. Because tissue-based sequencing compendia rely primarily on early stage and treatment-naïve tumors, these databases have generated limited insights into acquired resistance. Conversely, large cfDNA cohorts, which can more readily provide non-invasive access to patients with advanced disease, may offer unique insight into resistance mechanisms emerging under the selective pressure of systemic therapies. For example, the potential for EGFR ECD mutations to drive resistance to anti-EGFR antibodies has been documented through cfDNA and tumor biopsies from small patient cohorts (7,10,12,16-18). These efforts have identified key amino acid mutations that drive acquired resistance, including I462, S464, G465, K467 (Cluster 2) and K489, L491, S492 (Cluster 3) (7,18). Our cfDNA database analysis confirmed the recurrent alteration of these previously identified residues, but also identified a previously unreported cluster of EGFR ECD mutations involving V441 and S442 (Cluster 1) that accounted for 25% of all ECD mutations, representing an important and novel mechanism of resistance to EGFR blockade.

A key limitation of our study is the lack of clinical annotation for the cfDNA cohort. Indeed, since treatment history was not available for some patients with EGFR ECD mutations, it is not possible to confirm that all patients had received prior anti-EGFR antibody therapy. However, EGFR ECD mutations have not been observed in CRC prior to EGFR blockade, and accordingly, in the 57% of EGFR ECD patients with available treatment history, every patient was confirmed to
have received prior anti-EGFR therapy. While these factors support the likelihood that these alterations emerged in the setting of acquired resistance to anti-EGFR therapy, the absence of paired baseline samples makes this impossible to confirm. Still, it is notable that even without detailed clinical data, this analysis was able to generate new insights into resistance in CRC. Collectively, these findings demonstrate the potential of large-scale cfDNA profiling as a tool for discovery, and underscore the potential benefits of ongoing academic efforts to create publicly available cfDNA databases with clinical annotation for future studies (29).

Our study also provides key insights into the role of tumor heterogeneity in the setting of acquired resistance to anti-EGFR antibodies in CRC. Previous studies have illustrated that multiple, heterogeneous resistance alterations can be detected in the cfDNA of individual patients, which are thought to represent the existence of multiple resistant tumor subclones, often residing in different metastases throughout the body (5,7,8,16,18,19,24). Our study supports the frequent co-occurrence of multiple resistance alterations in individual patients following EGFR blockade, but suggests that the degree of molecular heterogeneity present may be even more profound and complex than anticipated. Indeed, we observed that patients harbored an average of 5 unique resistance alterations (median 4), with as many as 13 distinct resistance alterations observed in a single patient. In only 9% of patients was a single resistance alteration detected.

The degree of molecular heterogeneity observed following anti-EGFR therapy highlights the difficulty of devising a single therapeutic strategy capable of overcoming a broad array of resistance mechanisms, particularly since these alterations frequently affected multiple functionally distinct targets in an individual patient. These findings have profound clinical implications for efforts designed to overcome EGFR ECD mutations by binding multiple epitopes on EGFR (16,30,31). Indeed, our results suggest that the percentage of patients who
harbor EGFR ECD mutations alone may be exceedingly small—only 12% in this limited series (Fig. 4C). Therefore, tumor heterogeneity at the time of acquired resistance to EGFR blockade represents a significant obstacle to the development of precision medicine strategies, and suggests that therapeutic strategies that target a key convergent signaling node capable of overcoming the multiplicity of resistant clones present in an individual patient may be required (9,18). Collectively, these studies support the potential utility of large-scale cfDNA profiling databases to define the genomic landscape of cancer patients and to provide novel and clinically relevant insights into tumor heterogeneity and therapeutic resistance.

**Methods**

**cfDNA Cohort**

1,772 consecutive blood specimens were analyzed from patients with CRC using the Guardant360™ cfDNA assay (Guardant Health, Redwood City, CA). The Guardant360™ assay is a CLIA-certified targeted digital sequencing panel designed to detect single nucleotide variants (SNVs), as well as selected insertions/deletions, amplifications, and fusions (Supplementary Table S1). Subjects provided informed, written consent when appropriate. This research was conducted in accordance with the Declaration of Helsinki and was performed with IRB approval (MDACC LAB09-0373).

**Analysis of cfDNA mutational prevalence**

To determine cfDNA mutational prevalence, we analyzed samples in which at least one mutation was detected (N= 1,500). When more than one sample was available for the same patient, the most recent sample was selected for analysis. The final cfDNA analysis cohort included samples from 1,397 unique patients. Mutations considered in this analysis include single nucleotide polymorphisms that resulted in protein coding changes (ie missense/nonsense). Synonymous,
splice site, intron, intergenic, and untranslated region variants were not included in the prevalence calculation. Insertions/deletions (indels), fusions, and amplifications/deletions were also excluded. The primary focus for this analysis is on the twenty genes with the highest mutation prevalence.

**Analysis of tissue mutational prevalence**

To compare cfDNA mutational prevalence to that of tissue-based datasets, we obtained sequencing results from three previously reported and publicly available tumor tissue cohorts. The TCGA cohort consisted of 228 unique cases with tumor and matched normal tissue pairs with whole exome sequencing (WES) from the supplement of the original TCGA characterization of colon and rectal cancer (3). The NHS/HPFS cohort included WES of tumor and matched normal tissue pairs from 619 untreated colorectal cancers (4). The third cohort consisted of CRC cases from the AACR Project GENIE (13). Because profiling techniques differ across centers within the AACR Project GENIE, we limited our analysis to those centers that analyzed all exons of sequenced genes. This allowed prevalence calculations based on gene coverage comparable to the Guardant360™ assay. The proportions and 99% confidence intervals (CIs) of specific gene mutations were computed for all tissue and cfDNA cohorts. 99% confidence intervals for binomial proportions were calculated for each gene mutation based on the frequencies and numbers of patients studied using the modified Wald method (32). CIs were compared descriptively between the cfDNA cohort and each tissue-based cohort. Median age was compared between patients with and without a JAK2 V617F mutation detected in cfDNA using the t-test. Bar charts and scatter plots were used to illustrate the data.

**Analysis of clonal and subclonal mutations**

The twenty genes with the highest mutation prevalence were analyzed for percentage of variants that were either clonal or subclonal. This analysis included all non-synonymous SNV gene variants. In this analysis, when serial samples were available for the same patient, the sample with the highest MAF
was selected as the most representative for analysis. A mutation was defined as clonal if the MAF was greater than or equal to 25% of the highest MAF in the sample. A mutation was defined as “subclonal” if the MAF was less than 25% of the highest MAF in the sample.

**Analysis of Functional Significance of Alterations**

Functional annotation of variants for figure 2B was provided by the Precision Oncology Decision Support Core at Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy of The University of Texas MD Anderson Cancer Center (https://pct.mdanderson.org/). This annotation utilizes a large curated database of variants with literature based and *in vitro* assessment of functional significance (33,34).

**Determination of EGFR antibody binding**

NIH3T3 cells were obtained from ATCC (CRL-1658) in 2016 and were passaged for less than 6 months after receipt. Full-length human EGFR cDNA (Addgene 23935) was mutagenized using the Stratagene Site-Directed Mutagenesis Kit to produce V441D and V441G mutations. EGFR-containing pLenti-puro (Addgene 17452) was used to produce virus to infect NIH3T3 cells. Cells were infected with empty pLenti plasmid, wild type EGFR, EGFR V441D and EGFR V441G, and analyzed by flow cytometry for antibody binding as performed by others (17). Cells were analyzed by Western blot to demonstrate equal levels of EGFR expression. 1x10^6 cells of each type were resuspended in 100uL of 1% BSA in PBS, and incubated with 1ug of either cetuximab or panitumumab for 1 hour at 4°C. Cells were washed with 1% BSA in PBS, and incubated with 1ug of anti-human PE-conjugated secondary antibody (ThermoFisher H10104). Cells were washed and subsequently read on an LSRII flow cytometer. The antibody binding experiment was performed in triplicate. Molecular modeling was conducted using the program Insight II (Accelrys, San Diego).
Figure Legends

Figure 1: Genomic profiling by cfDNA or tumor tissue sequencing in CRC cohorts.

A.) Comparison of mutation frequencies in cfDNA and tissue cohorts (SNVs only). Top 20 gene mutations in cfDNA listed. Includes missense and nonsense mutations only (splice site mutations, insertions, and deletions excluded).

B.) Correlation between mutation frequencies in cfDNA versus tissue (top 20 genes in cfDNA listed).

C.) Comparison of JAK2 V617F mutation frequency in cfDNA and tumor tissue databases.

D.) Comparison of age between all patients with cfDNA profiling vs. patients with detectable JAK2 V617F mutation in blood.

Figure 2: Clonality of common gene mutations in cfDNA from patients with CRC

A.) Proportion of clonal vs. subclonal mutations in commonly mutated genes in cfDNA (top 20 genes in cfDNA listed).

B.) Impact of variant functional significance on clonality of the alteration.

C.) Scatter plot of KRAS mutant allele frequency versus APC mutant allele frequency. Patients with EGFR ECD mutations are labelled in red.

D.) Scatter plot of EGFR mutant allele frequency versus APC mutant allele frequency. Patients with EGFR ECD mutations are labelled in red.

Figure 3: EGFR ECD mutations in cfDNA

A.) EGFR ECD mutations occurring more than once in cfDNA cohort. Three dominant clusters of amino acid substitutions in the binding domain of anti-EGFR antibodies are shown.

B.) Molecular model of cetuximab bound to wild type EGFR V441 and EGFR V441D.
C.) Molecular model of cetuximab bound to wild type EGFR V441 and EGFR V441G.

D.) Binding assay of cetuximab and panitumumab to wild type, V441D, and V441G EGFR. ** indicates p<0.01 by one-way ANOVA with Tukey post-hoc test for cetuximab and panitumumab.

**Figure 4: Heterogeneity of anti-EGFR resistance alterations in patients with EGFR ECD mutations**
A.) (top) Known anti-EGFR antibody resistance alterations identified in cfDNA for patients with EGFR ECD mutations, with each row representing an individual patient.

(bbottom) Percentage of cases with alteration, with each bar representing mutational frequency

B.) Case examples of patients with multiple EGFR pathway alterations.

C.) Number of ECD (blue) and non-ECD (red) resistance alterations identified in cfDNA for each patient. Arrows indicate patients with EGFR ECD mutations only.
REFERENCES


Strickler et al, Figure 1

(A) Bar chart showing the percentage of mutations for different genes. The x-axis represents patient age in years, and the y-axis shows the percentage of mutated genes.

(B) Scatter plot illustrating the relationship between cfDNA prevalence and tissue prevalence. The dotted line represents a 99% confidence interval with a correlation coefficient of 0.95. The p-value is less than 0.0001.

(C) Table listing the frequency of JAK2 V617F mutations across different cohorts:

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>cfDNA</td>
<td>16/1397 (1.14%)</td>
</tr>
<tr>
<td>TCGA</td>
<td>0/228 (0%)</td>
</tr>
<tr>
<td>NHS/HPFS</td>
<td>0/619 (0%)</td>
</tr>
<tr>
<td>GENIE</td>
<td>0/1149 (0%)</td>
</tr>
<tr>
<td>All tissue</td>
<td>0/1996 (0%)</td>
</tr>
</tbody>
</table>

(D) Box plot comparing JAK2 V617F status across different patient age groups. The p-value is 0.0006.
Strickler et al, Figure 2

A

B

C

D

Percentage of variants (%)

Clonal
Subclonal

*p<0.05 by Chi-Square
**p<0.0001 by Chi-Square

KRAS MAF

APC MAF

EGR MAF

APC MAF

APC MAF
A

Strickler et al, Figure 3

Domain III (aa334-504)

Cluster 1 25%
V441G/D/F 19%
S442R/I 6%

Cluster 2 37%
I462K/R 2%
S464L/T 12%
G465R/E/V 20%
K467N/T 3%

Cluster 3 16%
K489Q/E 2%
I491K/R 4%
S492R/C 10%

B

EGFR WT

C

EGFR WT

D

Binding (% of WT EGFR)

** p < 0.01

EGFR V441D

EGFR V441G

Cetuximab
Panitumumab

Research.
on December 15, 2017. © 2017 American Association for Cancer
discovery.aacrjournals.org Downloaded from
Strickler et al, Figure 4

A

Patients

EGFR ECD

Amplification

KRAS

NRAS

MEK1

# of cases

% of cases

Any KRAS = 69%

Any NRAS = 33%

B

Pt #1

Pt #8

Pt #12

V411D, G469E, K487T, S492R

AMPA, G12A, G12C, G13D, Q81H

MET AMP

V411D, S446L, G465R

EGFR

ERBB2 AMP

EGFR

ERBB2 AMP

K61E

Any KRAS = 69%

Any NRAS = 33%

C

# resistance alterations

EGFR ECD

other non-EGFR ECD

Patients
Genomic landscape of cell-free DNA in patients with colorectal cancer


Cancer Discov  Published OnlineFirst December 1, 2017.

Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-17-1009

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2017/12/01/2159-8290.CD-17-1009.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerdiscovery.aacrjournals.org/content/early/2017/12/01/2159-8290.CD-17-1009.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.